Acknowledgments
The study was partially supported by the Italian Ministry of Health – Bando Ricerca Corrente 2022.
-
Research funding: None declared.
-
Author contribution: AT conceived the study and wrote the manuscript. ES and MC made laboratory testing, data analysis, and reviewed results. IA, EMF and MC selected patients and reviewed results. SP reviewed results and helped preparing the manuscript. FP reviewed results. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Informed consent was obtained from all individuals included in this study.
-
Ethical approval: The local Institutional Review Board exempted the protocol from review.
References
1. Kamath, PS, Wiesner, RH, Malinchoc, M, Kremers, W, Therneau, TM, Kosberg, CL, et al.. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–70. https://doi.org/10.1016/s0016-5085(01)80377-2.Search in Google Scholar
2. Chantarangkul, V, Tripodi, A, van den Besselaar, AMHP. Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy with vitamin K antagonists. WHO Tech Rep Ser 2013;979:273–305.Search in Google Scholar
3. Tripodi, A, Chantarangkul, V, Primignani, M, Fabris, F, Dell’Era, A, Sei, C, et al.. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007;46:520–7. https://doi.org/10.1002/hep.21732.Search in Google Scholar PubMed
4. Tripodi, A. How to implement the modified international normalized ratio for cirrhosis (INR(liver)) for model for end-stage liver disease calculation. Hepatology 2008;47:1423–4. https://doi.org/10.1002/hep.21989.Search in Google Scholar PubMed
5. ACL Top data reduction training manual. Revision; 2005.Search in Google Scholar
6. Poggio, M, van den Besselaar, AM, van der Velde, EA, Bertina, RM. The effect of some instruments for prothrombin time testing on the International Sensitivity Index (ISI) of two rabbit tissue thromboplastin reagents. Thromb Haemostasis 1989;62:868–74. https://doi.org/10.1055/s-0038-1651019.Search in Google Scholar
7. Montaruli, B, Guiotto, C, Cosseddu, D. Influence of hemolysis, icterus and lipemia on coagulation tests as performed on Cobas t511 new analyzer. Blood Coagul Fibrinolysis 2020;31:48–54. https://doi.org/10.1097/mbc.0000000000000873.Search in Google Scholar
8. Lippi, G, Plebani, M, Favaloro, EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. Semin Thromb Hemost 2013;39:58–66. https://doi.org/10.1055/s-0032-1328972.Search in Google Scholar PubMed
9. Nougier, C, Jousselme, E, Sobas, F, Pousseur, V, Négrier, C. Effects of hemolysis, bilirubin, and lipemia interference on coagulation tests detected by two analytical systems. Int J Lab Hematol 2020;42:88–94. https://doi.org/10.1111/ijlh.13147.Search in Google Scholar PubMed
10. Tripodi, A, Lippi, G, Plebani, M. How to report results of prothrombin and activated partial thromboplastin times. Clin Chem Lab Med 2016;54:215–22. https://doi.org/10.1515/cclm-2015-0657.Search in Google Scholar PubMed
© 2023 Walter de Gruyter GmbH, Berlin/Boston
